Abstract:Aims: Left ventricular hypertrophy (LVH) is frequently detected via echocardiography in individuals with Fabry disease (FD), sometimes leading to confusion with hypertrophic cardiomyopathy (HCM) of other aetiologies. Considering this diagnosis challenge, FD should be included in the list of differential diagnosis for patients presenting with LVH. To address this concern, we conducted a prospective screening study in China, using dried blood spot (DBS) testing, to evaluate patients with unexplained LVH. Methods: Our study was designed as a nationwide, multicentre prospective investigation. A total of 1015 patients from 55 different centres who were diagnosed with LVH by echocardiography were screened in the study from September 2022 to December 2023. Demographic information, biochemistry data, echocardiography parameters and clinical observations were meticulously collected from all participants. The DBS method was used to assess α-galactosidase A (α-Gal A) activity in males and both α-Gal A and globotriaosylsphingosine (lyso-Gb3) levels in females. Results: The final screening population included 906 patients (589 males, 65%) with LVH, characterized by a mean maximal myocardial thickness of 14.8 ± 4.6 mm and an average age of 56.9 ± 17.2 years. In total, 43 patients (38 males, 5 females) exhibited low α-Gal A activity measurement (<2.2 μmol/L), while 21 patients (10 males, 11 females) presented low α-Gal A activity or elevated lyso-Gb3 levels (>1.1 ng/mL). Among these patients, eight individuals (7 males and 1 female) were genetically confirmed to harbour pathogenic GLA mutations, resulting in a total prevalence of 0.88%. Compared with patients without FD, patients with FD tended to have proteinuria (75% vs. 21.2%, P = 0.001), family history of HCM (37.5% vs. 2.3%, P < 0.01) and neuropathic pain (37.5% vs. 4.4%, P < 0.01) but lower systolic blood pressure (118.5 ± 12.5 vs. 143.3 ± 29.3 mmHg, P = 0.017). Five mutations were previously recognized as associated with FD while the remaining two, p.Asp313Val (c.938A>T) and c.547+3A>G, were deemed potentially pathogenic. Subsequent familial validation post-diagnosis identified an additional 14 confirmed cases. Conclusions: This pioneering screening study for FD among Chinese patients with unexplained LVH using DBS measurement, revealed an FD detection rate of 0.88%. Our findings confirmed that the combined measurement of lyso-Gb3 and α-Gal A activity is beneficial for primary screening of FD in patients with LVH. Given the availability of efficacious therapies and the value of cascade screening in extended families, early detection of FD in LVH patients is clinically important.

Investigating undiagnosed Fabry disease in young adults with ischemic stroke: A multicenter cohort study

Screening for Fabry's Disease in Young Patients with Ischemic Stroke in a Chinese Population

Lifestyle Risk Factors for Ischemic Stroke and Transient Ischemic Attack in Young Adults in the Stroke in Young Fabry Patients Study

High Incidence of the Cardiac Variant of Fabry Disease Revealed by Newborn Screening in the Taiwan Chinese Population

Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry

Enzyme Assay and Clinical Assessment in Subjects with a Chinese Hotspot Late-Onset Fabry Mutation (IVS4 + 919G→A)

Revisited Later-Onset Cardiac Type Fabry Disease: Cardiac Damage Progresses in Silence (experiences from an Extremely High Prevalent Area, Taiwan)

Endomyocardial Biopsies in Patients with Left Ventricular Hypertrophy and a Common Chinese Later-Onset Fabry Mutation (IVS4 + 919G > A)

Stroke rates, risk factors, and aspirin prescribing trends in the Canadian Fabry Disease Initiative cohort

Clinical profile , risk factors and aetiology of young ischaemic stroke patients in Asia : A prospective , multicentre , observational , hospital-based study in eight cities 1

Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study

Risk Factors, Treatments, and Outcomes of Adults Aged <55 Years With Acute Ischemic Stroke With Undetermined Versus Determined Pathogenesis: A Nationwide Swiss Cohort Study

Association between Liver Fibrosis and Stroke Recurrence in Young Patients with Ischemic Stroke

Age- And Gender-Specific Prevalence Of Risk Factors In Patients With First-Ever Ischemic Stroke In China

Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease

Etiologic Study of Young Ischemic Stroke in Taiwan

Effects of Enzyme Replacement Therapy for Cardiac-Type Fabry Patients with a Chinese Hotspot Late-Onset Fabry Mutation (IVS4+919G>A)

Association of elevated lipoprotein(a) levels with ischemic stroke in young patients - a systematic review and meta-analysis

Age at First Cardiac Symptoms in Fabry Disease: Association with a Chinese Hotspot Fabry Mutation (IVS4+919G>A), Classical Fabry Mutations, and Sex in a Taiwanese Population from the Fabry Outcome Survey (FOS).

Differences in Cardiac Etiologies for Ischemic Stroke in Young and Middle-Aged Patients: A Single-Center Experience in Taiwan

Etiology and risk factors of intracranial hemorrhage and ischemic stroke in young adults